AT9283 lactic acid
Based on 10 publication(s) in Google Scholar
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 896466-76-5
- Fòrmula: C22H29N7O5
- Peso molecular:471.51
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-50514
AT9283Aurora/JAK Inhibitor -
HY-16379
PacritinibJAK2/FLT3 Inhibitor -
HY-40354A
Tofacitinib citrateJAK1/JAK3 Inhibitor -
HY-10409
FedratinibJAK2 Inhibitor -
HY-10179
DanusertibAurora Kinase Inhibitor -
HY-15508
JANEX-1JAK Inhibitor -
HY-N0104
CurcumolApoptosis Inducer -
HY-10987A
ENMD-2076 -
HY-50514R
AT9283 (Standard)Aurora/JAK Inhibitor -
HY-14346
PD153035EGFR Inhibitor -
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-13253
AMG 900Aurora Kinase Inhibitor
Publications Citing Use of MedChemExpress (MCE) AT9283 lactic acid
More- J Adv Res. 2024 Feb:56:1-14. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- PLoS Pathog. 2022 Jun 13;18(6):e1010620. [Abstract]
- Cancers (Basel). 2022 Mar 19;14(6):1575. [Abstract]
- Front Oncol. 2021 Jun 18:11:656608. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- SSRN. 2026 Jun 30.
- University of Washington. 2025.
- bioRxiv. 2025 February 21.
- Patent. US20180263995A1.
Ver todos los productos específicos de isoformas Aurora Kinase
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Aurora A 3 nM (IC50) |
Aurora B 3 nM (IC50) |
JAK3 1.1 nM () |
JAK2 1.2 nM () |
ABL(T315I) 4 nM () |
Chemical Information
-
No. CAS 896466-76-5
-
Peso molecular 471.51
-
Fòrmula C22H29N7O5
-
SMILES
O=C(NC1CC1)NC2=CNN=C2C3=NC(C=C4)=C(C=C4CN5CCOCC5)N3.O=C(O)[C@H](C)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection. [Abstract]2024 Feb:56:1-14. PMID: 36894120 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
PLoS Pathog
Bile acids promote the caveolae-associated entry of swine acute diarrhea syndrome coronavirus in porcine intestinal enteroids. [Abstract]2022 Jun 13;18(6):e1010620. PMID: 35696443 -
Cancers (Basel)
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]2022 Mar 19;14(6):1575. PMID: 35326726 -
Front Oncol
GEFT Inhibits Autophagy and Apoptosis in Rhabdomyosarcoma via Activation of the Rac1/Cdc42-mTOR Signaling Pathway. [Abstract]2021 Jun 18:11:656608. PMID: 34221974 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
-
-
-
Pureza y Documentación
Referencias
[1]. Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388. [Content Brief]
[2]. Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AT9283 lactic acid Related Classifications
HY-10058 Related Classifications
Powered by Bioz